ASH News Daily 2013 - Day 2 - (Page B-28)
preventive dentistry prior to treatment with bisphosphonate
dental procedures, if possible, as recovery may be prolong
bisphosphonate therapy, dental surgery may exacerbate th
procedures, there are no data available to suggest wheth
treatment reduces the risk of ONJ. A causal relationship be
(These acknowledgments reflecthas not been established. Clinical judgment of the treating ph
contributions made prior to October 22, 2013.)
plan of each patient based on individual benefit/risk assessm
ZOMETA should not be used during pregnancy. Women of ch
to avoid becoming pregnant.
ASH Bridge grAnt ProgrAm If the patient becomes pregnan
The Society thanks the following companies who supported this program in apprised of the potential harm
this drug, the patient should be 2013:
In postmarketing experience, severe and occasionally incapa
has been reported in patients taking bisphosphonates includ
symptoms develop, and a subset of patients had recurrenc
the same drug or another bisphosphonate. There have bee
sensitive patients receiving bisphosphonates.
Insufficient data exist on how to safely use ZOMETA in HCM
Acute-phase reaction symptoms can occur in HCM patient
with ZOMETA vs. 33% with pamidronate). Patients may oc
chills, flushing, bone pain and/or arthralgias and myalgias). The
About the Bridge Grant Award
* ASH membership is causality, with ZOMETA
clinical trials, regardless of required at the time of applica-4 mg (n=
tion to the anemia (22%), dyspnea (22%),
This year and for the next two years, ASH's constipation (27%),Bridge Grant program and throughout diarrhe
Bridge
the award period.
Grant program will provide at least 30 one-year
cancer (16%), insomnia (15%), vomiting (14%), anxiety (14%
awards annually, in the amount of $100,000 each, to * There are two award cycles per year.
(13%), confusion (13%), agitation (13%), moniliasis (12%
ASH members who applied for an NIH R01 grant or * The Society is currently seeking support from indipain (12%), hypotension (11%), and hypomagnesemia (11%
vidual and corporate donors in order to provide adequivalent but were denied funding due to budget cut(5-10% frequency) occurring in greater incidence with ZOME
ditional awards.
backs. The long-term goal of the award is to help sustain
leg edema, mucositis, dysphagia, granulocytopenia, throm
recipients' research and contribute to their retention in
Award dehydration, arthralgias, headache and somnol
hematology investigation.
hypocalcemia,Timeline
Fourth Round
been infrequently reported.
Application deadline:
Additional Details
The most common adverse events (≥15%) in bone metastas
* From 2013 through 2015, ASH will award 90 ASH April 1, 2014
4 mg Applicant were as follows: bone pain (55%), nausea
members (30 per year) with $100,000 Bridge Grants, (n=1031) notification of acceptance:
vomiting (32%), constipation (31%), dyspnea (27%), diarrh
Mid-to-late June 2014
for a $9 million total investment.
(22%), cough (22%), arthralgia (21%), lower-limb edema (21
(19%), dizziness (excluding vertigo) (18%), insomnia (16%), de
(15%). Patients should also be made aware of the potential f
ASH trAnSlAtionAl reSeArcH trAining in HemAtology
Ocular adverse events may occur with bisphosphonates, in
The Society thanks the following companies who supported this program in 2013:
conjunctivitis, iritis, and orbital inflammation including orbital
some cases, symptoms resolved with topical steroids.
Caution is advised when bisphosphonates, including ZOMET
and potentially nephrotoxic drugs.
Patients with multiple myeloma and bone metastases due
supplement of 500 mg and a multiple vitamin containing 400
2013 ASH Award Supporters
References: 1. Rosen LS, Gordon D, Kaminski M, et al; Zoledronic Acid Breast Cancer
compared with pamidronate disodium in the treatment of skeletal complications in pa
blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744. 2. Wu EQ, Bensim
patterns associated with early vs. delayed zoledronic acid therapy in multiple myelom
et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Pr
Please see full Prescribing Information.
Please see brief summary of full Prescribing Information on the
© 2011 Novartis
September 20
Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 2
Table of Contents
ASH News Daily 2013 - Day 2
https://www.nxtbookmedia.com